Abstracts Archive - Page 1410 of 2425 - ACR Meeting Abstracts

Abstract Number: 27 • 2017 Pediatric Rheumatology Symposium
Assessing the Safety of Kidney Biopsies Performed on Childhood-onset Systemic Lupus Erythmatosus Patients
Shreya Goyal¹, Daniel Ashton^2,3, Kamlesh Kukreja^3,4, Michael C. Braun^5,6 and Scott E. Wenderfer^5,7, ¹Pediatrics, Baylor College of Medicine, Houston, TX, ²Interventional Radiology, Texas Children's Hospital, Houston, TX, ³Radiology, Baylor College of Medicine, Houston, TX, ⁴Interventional RAdiology, Texas Children's Hospital, Houston, TX, ⁵Texas Children's Hospital, Houston, TX, ⁶Pediatrics-Renal, Baylor College of Medicine, Houston, TX, ⁷Pediatrics-Renal, Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Title: Assessing the Safety of Kidney Biopsies Performed on Childhood-onset Systemic Lupus Erythematosus Patients Background/Purpose: There is very little data in the literature on…
Abstract Number: 2 • 2017 Pediatric Rheumatology Symposium
Murine Model of Arthritis Flare Identifies CD8+ Tissue Resident Memory T Cells in Recurrent Synovitis
Margaret H Chang¹, Anais Levescot², Allyn Morris², Nathan Nelson-Maney³, Robert Fuhlbrigge⁴ and Peter A. Nigrovic², ¹Immunology, Boston Children's Hospital, Boston, MA, ²Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital, Boston, MA, ³Division of Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital, Boston, MA, ⁴Children's Hospital Colorado, Aurora, CO
Background/Purpose: There are 75,000 children affected by JIA in the United States. Despite recent therapeutic advances, treatment often requires chronic therapy and is associated with…
Abstract Number: 109 • 2017 Pediatric Rheumatology Symposium
Clinical features of pediatric Behçet’s disease patients in Japan
Ken-ichi Yamaguchi¹ and Satoshi Fujikawa², ¹Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ²Immuno－Rheumatology Center, St.luke's International Hospital, Tokyo, Japan
Background/Purpose: To diagnose pediatric patients as Behçet’s disease (BD) is challenging. Sensitivity of four BD criteria, three BD criteria made for adult patients and Paediatric…
Abstract Number: 14 • 2017 Pediatric Rheumatology Symposium
Efficacy and Safety of Canakinumab in Patients with Periodic Fever Syndromes (Colchicine-Resistant FMF, HIDS/MKD and TRAPS): Results from a Phase 3, Pivotal, Umbrella Trial
Fabrizio De Benedetti¹, Jordi Anton², Eldad Ben-Chetrit³, Inmaculada Calvo⁴, Joost Frenkel⁵, Marco Gattorno⁶, Hal M. Hoffman⁷, Ozgur Kasapcopur⁸, Isabelle Koné-Paut⁹, Helen Lachmann¹⁰, Michel Moutschen¹¹, Seza Ozen¹², Pierre Quartier¹³, Anna Simon¹⁴, Andrew Zeft¹⁵, Karine Lheritier¹⁶, Antonio Speziale¹⁶ and Guido Junge¹⁶, ¹IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ²Unitat de Reumatologia Pediàtrica, Hospital Sant Joan de Déu, Barcelona, Spain, ³Rheumatology Unit, Hadassah—Hebrew University Medical Center, Jerusalem, Israel, ⁴Hospital Universitario y Polytecnico La Fe, Valencia, Spain, ⁵University Medical Center,Utrecht, Utrecht, Netherlands, ⁶Pediatric Rheumatology, G. Gaslini Institute, Genoa, Italy, ⁷Division of Rheumatology, Allergy, and Immunology, University of California at San Deigo, La Jolla, CA, ⁸Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University, Istanbul, Turkey, ⁹Hopital Kremlin Bicetre, University of Paris SUD, Paris, France, ¹⁰UK National Amyloidosis Centre, University College London Medical School, London, United Kingdom, ¹¹CHU de Liège/ University of Liège, Liège, Belgium, ¹²Department of Pediatrics, Hacettepe University, Ankara, Turkey, ¹³Necker-Enfants Malades Hospital, Paris, France, ¹⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ¹⁵Pediatrics Rheumatology, Cleveland Clinic, Cleveland, OH, ¹⁶Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Open-label studies have suggested the efficacy of canakinumab (CAN), a fully human, highly specific anti-IL-1β neutralizing monoclonal antibody, in colchicine-resistant-FMF (crFMF), hyper-immunoglobulin (Ig) D…
Abstract Number: 8 • 2017 Pediatric Rheumatology Symposium
Examination of Reported Risk Loci from Candidate Gene Studies of Systemic Juvenile Idiopathic Arthritis Identifies Link between IL1RN Variation and both Disease Susceptibility and Response to Interleukin-1 Directed Therapy
Victoria Arthur¹, Emily Shuldiner¹, Anne Hinks², The International Childhood Arthritis Genetics (INCHARGE) Consortium³, Patricia Woo⁴, Wendy Thomson², Elaine F. Remmers⁵ and Michael J. Ombrello¹, ¹Translational Genetics and Genomics Unit, NIAMS, NIH, Bethesda, MD, ²Arthritis Research UK Centre for Genetics and Genomics,The University of Manchester, Manchester, United Kingdom, ³INCHARGE Consortium, Bethesda, MD, ⁴Paediatric Rheumatology Unit, University College London, London, United Kingdom, ⁵Inflammatory Disease Section, NHGRI, NIH, Bethesda, MD
Background/Purpose: Systemic JIA (sJIA) is a childhood inflammatory disease whose pathophysiology is poorly understood. sJIA is phenotypically heterogeneous with variable manifestations and responses to treatment.…
Abstract Number: 18 • 2017 Pediatric Rheumatology Symposium
Bridging the gap between GWAS and mechanism in juvenile idiopathic arthritis using a novel high-throughput experimental screen
Gang Li¹, Marta Martinez-Bonet¹, Di Wu², Jing Cui³ and Peter A. Nigrovic^1,4, ¹Brigham and Women's Hospital, Boston, MA, ²University of North Carolina, Chapel Hill, Chapel Hill, NC, ³Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Division of Immunology, Boston Children's Hospital, Boston, MA
Background/Purpose: Genome wide association studies (GWAS) have identified 27 non-HLA loci that convey risk for oligoarticular and seronegative polyarticular JIA. Most associated haplotypes bear no…
Abstract Number: 85 • 2017 Pediatric Rheumatology Symposium
Characteristics of anti-MDA5 autoantibody-associated Juvenile Dermatomyositis (JDM) in North America
Gulnara Mamyrova¹, Takayuki Kishi², Ira N Targoff³, Rodolfo V Curiel¹, Frederick W Miller², Lisa G Rider^1,2 and The Childhood Myositis Heterogeneity Collaborative Study Group, ¹Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, ²Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institute of Health, Bethesda, MD, ³VA Medical Center, University of Oklahoma Health Sciences Center, and Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Anti-MDA5 Abs have been reported to associate with clinically amyopathic and classic dermatomyositis (DM), with severe progressive interstitial lung disease (ILD) and poor prognosis…
Abstract Number: 157 • 2017 Pediatric Rheumatology Symposium
Utility of Mailed Reminders for Uveitis Screening Guidelines in Patients with Juvenile Idiopathic Arthritis
Laura Ballenger¹ and Kyla Driest², ¹Nationwide Children's Hospital, Columbus, OH, ²Rheumatology, Nationwide Children's Hospital, Columbus, OH
Background/Purpose: Uveitis is a major complication in patients with juvenile idiopathic arthritis (JIA) and can be completely asymptomatic until vision loss develops. In order to…
Abstract Number: 72 • 2017 Pediatric Rheumatology Symposium
Systemic Juvenile Idiopathic Arthritis in a Colombian cohort: onset and clinical course
Angela Mosquera, Clara Malagón and Christine Arango, Pediatric Rheumatology, Pediatric rheumatology post graduate program El Bosque University, Bogota, Colombia
Background/Purpose: Juvenile idiopathic arthritis is the most prevalent rheumatic disease in children. The systemic form accounts for 10-15% of cases and is characterized by a…
Abstract Number: 40 • 2017 Pediatric Rheumatology Symposium
Perspectives of young people with Juvenile Idiopathic Arthritis, their caregivers, and health care providers on transition to adult care: Informing development of a transition toolkit
Nadia Luca¹, Evelyn Rozenblyum², April Elliott³, Lynn R. Spiegel⁴, Nicole Johnson⁵, Sara Ahola Kohut⁶, Yvonne Brandelli³, Carolyn Johns⁷, Stephanie Luca⁸, Dianne P. Mosher⁹, Gordon Soon¹⁰, Karine Toupin-April¹¹, Gabriela Uifalusi³ and Jennifer N. Stinson¹², ¹Pediatric Rheumatology, University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada, ²Royal University Hospital, Saskatoon, SK, Canada, ³Alberta Children's Hospital, Calgary, AB, Canada, ⁴Rheumatology/Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada, ⁵Pediatrics, University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada, ⁶Hospital for Sick Children, Toronto, ON, Canada, ⁷Alberta Health Services, Calgary, AB, Canada, ⁸The Hospital for Sick Children, Toronto, ON, Canada, ⁹Med, University of Calgary, Calgary, AB, Canada, ¹⁰Pediatric Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, ¹¹Children’s Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada, ¹²Anesthesia and Pain Medicine, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: A seamless transition from pediatric to adult care is critical to ensure optimal health outcomes in adolescents and young adults with Juvenile Idiopathic Arthritis…
Abstract Number: 47 • 2017 Pediatric Rheumatology Symposium
Baseline characteristics of the first 123 patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA comparative effectiveness study
Sarah Ringold¹, George A. Tomlinson², Pamela F. Weiss³, Laura E. Schanberg⁴, Brian M. Feldman⁵, Mary Ellen Riordan⁶, Anne C. Dennos⁷, Vincent Del Gaizo⁸, Kate Murphy⁹, Yukiko Kimura⁶ and the CARRA Registry Investigators, ¹Seattle Children's Hospital, Seattle, WA, ²Medicine, Mount Sinai Hospital, Toronto, ON, Canada, ³Division of Rheumatology, Center for Pediatric Clincial Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Pediatrics, Duke Medical Center, Durham, NC, ⁵Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ⁶Hackensack University Medical Center, Hackensack, NJ, ⁷Duke Clinical Research Institute, Durham, NC, ⁸Parent Partner, Whitehouse Station, NJ, ⁹Patient Partner, San Francisco, CA
Background/Purpose: Many new effective treatments for polyarticular JIA (p-JIA) are available, but there is significant variation among pediatric rheumatologists in the timing of when biologic…
Abstract Number: 105 • 2017 Pediatric Rheumatology Symposium
Isolated Pediatric Pulmonary Capillaritis: A Comprehensive Single-Center Review of Disease Course, Management, and Prognosis
William Lapin¹, Saimun Singla², Eyal Muscal³ and Manuel Silva-Carmona⁴, ¹Department of Pediatrics, Division of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²Department Pediatrics, Division of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ³Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ⁴Department of Pediatrics, Pulmonology Section, Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Pediatric diffuse alveolar hemorrhage (DAH) is a life-threatening disorder characterized by pulmonary hemorrhage and respiratory insufficiency. Histologically, DAH with capillary inflammation is known as…
Abstract Number: 124 • 2017 Pediatric Rheumatology Symposium
Underutilization of Social Workers for Mental Health Care of Adolescents in Pediatric Rheumatology: A Mixed Methods Study
Andrea Knight^1,2, Michelle Vickery³, Lauren Faust⁴, Eyal Muscal⁵, Alaina M. Davis⁶, Julia Harris⁷, Aimee O. Hersh⁸, Martha Rodriguez⁹, Karen Onel¹⁰, Laura E. Schanberg¹¹, Tamar Rubinstein¹², Nina Washington^13,14, Elissa Weitzman^15,16, Hana Conlon¹⁷, Dana Gerstbacher¹⁸, Jennifer Woo¹⁹ and Emily Von Scheven²⁰, ¹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Center for Pediatric Clinical Effectiveness & PolicyLab, Philadelphia, PA, ³PolicyLab, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Children's Hospital of Philadelphia, Philadelphia, PA, ⁵Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ⁶Pediatric Rheumatology, Monroe Carell Junior Children's Hospital at Vanderbilt, Division of Pediatric Rheumatology, Nashville, TN, ⁷Children's Mercy Kansas City, Kansas City, MO, ⁸Pediatrics/Rheumatology, University of Utah, Salt Lake City, UT, ⁹Pediatrics, University of Chicago Medical Center, Chicago, IL, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹Pediatrics, Duke Medical Center, Durham, NC, ¹²Albert Einstein College of Medicine, Children's Hospital at Montefiore, New York, NY, ¹³University of Mississippi Medical Center, Jackson, MS, ¹⁴Dept. of Pediatric Rheumatology, University of Mississippi Medical Center, Jackson, MS, ¹⁵Boston Children's Hospital, Boston, MA, ¹⁶Harvard Medical School, Boston, MA, ¹⁷Columbia University, New York, NY, ¹⁸Stanford University, Palo Alto, CA, ¹⁹University of California Los Angeles, Los Angeles, CA, ²⁰Dept of Pediatric Rheumatology, Univ of California San Francisco, San Francisco, CA
Background/Purpose: Mental health problems are common, but undertreated in adolescents with rheumatologic conditions. As social workers help manage medical and psychosocial aspects of illness, we…
Abstract Number: 35 • 2017 Pediatric Rheumatology Symposium
Kv1.3 Expression on Urinary Leukocytes in Lupus Nephritis: Potential for Targeted Immunotherapy
Anne Stevens¹, Andrew Hinkle², Megan Yuasa³, David Peckham⁴, Chelsea Olsen⁵, Craig Philips⁵, Shawn P. Iadonato⁴ and Peter Probst⁶, ¹University of Washington, Pediatrics, Seattle, WA, ²Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA, ³Seattle Children’s Research Institute, Seattle, WA, ⁴Kineta Inc, Seattle, WA, ⁵KPI Therapeutics, Inc., Seattle, WA, ⁶Kineta, Inc, Seattle, WA
Background/Purpose: Lymphocyte activation depends upon a calcium signaling cascade that is regulated by voltage-gated potassium channels. Effector memory T cells (TEM), which are implicated in…
Abstract Number: 133 • 2017 Pediatric Rheumatology Symposium
3-D Explant Method Facilitates the Study of Lymphocytes in Synovium and Reveals a Population of Resident Memory-Like T Cells in Rheumatoid Arthritis
Lauren Henderson¹, Deepak Rao², Nikola Teslovich^3,4, Sandra King⁵, Fumitaka Mizoguchi⁶, Sarah Ameri⁶, Allyn Morris⁷, Christopher Elco⁵, Margaret Chang⁸, Anais Levescot⁹, James Lederer¹⁰, Scott Martin¹¹, Barry Simmons¹¹, John Wright¹¹, Michael Brenner², Soumya Raychaudhuri^{12,13,14,15,16}, Robert Fuhlbrigge¹⁷ and Peter Nigrovic^1,18, ¹Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Program in Medical and Population Genetics, Broad Institute of Massachusetts Technical Institute and Harvard University, Cambridge, MD, ⁴Divisions of Genetics and Rheumatology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ⁵Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁶Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁷Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA, ⁸Division of Immunology, Boston Children's Hospital, Boston, MA, ⁹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, boston, MA, ¹⁰Department of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹¹Department of Orthopedic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ¹²Divisions of Genetics and Rheumatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ¹³Program in Medical and Population Genetics, Broad Institute of Massachusetts Technical Institute, Harvard University, Cambridge, MA, ¹⁴Partners Center for Personalized Genetic Medicine, Boston, MA, ¹⁵Institute of Inflammation and Repair, University of Manchester, Manchester, United Kingdom, ¹⁶Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital Solna, Stockholm, Sweden, ¹⁷Children's Hospital Colorado, Aurora, CO, ¹⁸Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Tissue resident memory T (TRM) cells survive indefinitely in barrier tissues and mediate swift immunologic memory responses at sites of microbe entry. TRM cells…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].